Wakunaga Pharmaceutical Co.,Ltd

Zerbaxa is a combination drug containing ceftolozane, a cephalosporin antibacterial drug, and tazobactam, a beta-lactamase inhibitor. Zerbaxa was approved by the FDA and the EMA to treat complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). Zerbaxa is put on sale by Merck & Co., Inc.
Collaboration: Astellas Pharma Inc.
Licensee: Cubist Pharmaceuticals

Official Website
https://www.merckconnect.com/zerbaxa/overview.html　

Baxdela is a fluoroquinolone antibiotic that exhibits activity against both gram-positive and gram-negative pathogens, including MRSA. On 19th June 2017, the U.S. Food and Drug Administration (FDA) has approved Baxdela, indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
Licensee: Melinta Therapeutics

Website
http://melinta.com/pipeline/baxdela/

We have been investigating antibiotics targeting gram-negative and drug-resistant bacteria. Recently, we discovered WFQs with high activity and efflux-avoidance nature, and presented their profiles in ASM Microbe 2016 (News Release in 2016). We are looking for business partners to develop them (Contact Us)

Tumor microenvironment program